Ionis Signs an Exclusive WW License Agreement with Bicycle to Develop Targeted Oligonucleotide Therapeutics Using TfR1 Bicycle Technology
Shots:
- Bicycle receives $45M as up front and is eligible to receive development- regulatory and commercial milestones along with royalties for each program developed under the collaboration
- Ionis exercised its option for an exclusive license under the terms of a Dec’2020 evaluation and option agreement and get rights to evaluate tissue-targeting TfR1 binding Bicycles as vehicles to deliver oligonucleotide therapeutics and an option to obtain an exclusive license at the end of the evaluation period
- Bicycle retains the rights to use TfR1 Bicycles for all non-oligonucleotide therapies. Currently- Bicycle collaborates with DDF to advance potential TfR1 Bicycles for dementia
Ref: Business Wire | Image: Bicycle Therapeutics
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com